Physicians and researchers from the United States and around the world will present groundbreaking research from late-breaking clinical trials, follow-up data from major randomized trials and registries, and first-in-man experiences with novel devices or drugs. A multidisciplinary, international panel of expert physicians, scientists, and regulators will ask questions and shed light on the lasting impact of the research results presented.
Note: Submissions are currently closed. Please check back in May of 2019.
Research must be original and may not have been presented prior to presentation at VIVA. Abstracts must be submitted electronically via the official VIVA abstract submission website. Paper submissions will not be accepted.
Abstract submissions should address areas of endovascular medicine and report the results of:
Abstract submissions must include:
Total abstract length may not exceed 2,500 characters, exclusive of title or figures.
The following information must be provided upon submission:
Submitted abstracts will be reviewed after the submission deadline. Abstracts will be evaluated and scored based on the following criteria:
Notification of acceptance or rejection will be sent the week of September 10. The acceptance letter will be followed up with an additional letter that will include complete information regarding presentation of abstracts, including date and time of presentation and press conference. Non-VIVA faculty presenters whose abstracts are selected will be given complimentary registration to VIVA, but will be responsible for their own travel and accommodations.
If you have questions please contact Rachel DeLuna via e-mail: firstname.lastname@example.orgSubmissions will reopen summer 2019